Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Theralase raises C$4.76M to fund cancer drug trials and toxicology studies

TLT

$84.68

+$0.46 +0.55%

Theralase raises C$4.76M to fund cancer drug trials and toxicology studies

Name: Pluang-Trading US Stock Crypto
Availability: InStock
Rating: 4.75 (118347 reviews)
Author: pluang

Company Fundamentals

20 May 2026

Newsfile Corp

View Source

Bullish

Theralase Technologies Inc. completed a private placement raising C$4.76 million to support its Phase II bladder cancer clinical trial and begin toxicology studies for its drug Rutherrin®. The financing includes brokered and non-brokered offerings with units consisting of shares and warrants exercisable until 2031. The funds will also support working capital and general corporate purposes. The company aims to file new drug applications for Ruvidar® with Health Canada and the FDA, targeting approvals for bladder cancer treatment, and plans further clinical development for Rutherrin® in multiple cancer types pending regulatory approval.

More News (TLT)

Leveraged Treasury ETF TMF shows high risk and no clear buy signals amid volatile bond market.

The Direxion Daily 20+ Year Treasury Bull 3X ETF (TMF) offers triple leveraged exposure to long-term U.S. Treasury bonds, amplifying both gains and losses daily. Due to its daily leverage reset, TMF is better suited for short-term trading rather than...

Technical Signals

Bearish

4 days ago